Boston Scientific (NYSE: BSX) names Fitzgerald COO, splits into 3 segments

What happened

Boston Scientific Corporation (NYSE: BSX) said Joseph M. Fitzgerald will become executive vice president and chief operating officer on Jan. 1, 2027. He is now executive vice president and group president, Cardiovascular, a role he has held since May 2022. The company also said it will create three reportable segments, Interventional Therapies, Rhythm Solutions and MedSurg, on the same date.

Lance Bates will lead Interventional Therapies, Nick Spadea-Anello will lead Rhythm Solutions and Stephen Morse will lead MedSurg and Asia Pacific. All three will report to Fitzgerald. Interventional Therapies will include the Penumbra business after the anticipated close of the acquisition. The filing also says Fitzgerald joined Boston Scientific in 1990. Emily Woodworth (Collins) will remain chief accounting officer until March 1, 2027, when Mark Bickel takes over.

Key numbers

Metric	Latest	Change	Source
Reportable segments	3 segments		Boston Scientific press release
Annual base salary	$1.05 million		SEC 8-K
Annual bonus target	110%		SEC 8-K
2027 annual equity award	$7 million		SEC 8-K
Equity vesting	25% per year		SEC 8-K

Read more: Boston Scientific (BSX) stock analysis and investment case

Why it matters

The new operating model is meant to give the company more room to focus on long-term growth priorities and let businesses move faster and stay close to customers and patients. OptimistFi's case is that Boston Scientific turns recurring demand for less-invasive interventional medical devices, clinical-led product innovation and scale into durable revenue growth, expanding margins and rising free cash flow.

The filing is mixed for that view because it changes management and reporting lines, but it stops at structure. Fitzgerald's offer letter sets a $1.05 million base salary, a 110% annual bonus target and a $7 million equity award for 2027, which gives investors a pay baseline for the new COO.

Fitzgerald can defer up to 75% of each annual bonus award, and the equity grant vests 25% per year. The retirement plan benefit is capped at 36 months. The counterweight is that the reorganization is future-effective, and the Penumbra segment depends on the anticipated close of the acquisition. The filing also says Woodworth's transition is not due to any disagreement with the company.

Browse: stock research on every company OptimistFi covers

What's next

On Jan. 1, 2027, Fitzgerald is scheduled to take the COO role and the three reportable segments are set to begin. Boston Scientific said the 2027 equity award is expected in February 2027.

Woodworth and Bickel are scheduled to complete the chief accounting officer transition on March 1, 2027. A smooth rollout and the anticipated Penumbra close would support the new setup. A delay in the acquisition would leave the structural shift without an operating impact.

More from OptimistFi